Neopterin and biopterin levels and tryptophan degradation in patients with diabetes.
Adolescent
Adult
Aged
Aged, 80 and over
Biopterins
/ blood
Diabetes Mellitus, Type 1
/ blood
Diabetes Mellitus, Type 2
/ blood
Female
Humans
Hypoglycemic Agents
/ therapeutic use
Insulin
/ therapeutic use
Kynurenine
/ blood
Male
Metformin
/ therapeutic use
Middle Aged
Neopterin
/ blood
Tryptophan
/ blood
Vildagliptin
/ therapeutic use
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 10 2020
12 10 2020
Historique:
received:
18
05
2020
accepted:
28
09
2020
entrez:
13
10
2020
pubmed:
14
10
2020
medline:
29
12
2020
Statut:
epublish
Résumé
This study aimed to evaluate the possible changes of neopterin, biopterin levels and tryptophan degradation in diabetes and to compare the results within diabetes groups and with healthy subjects. Diabetes mellitus patients and healthy controls were recruited the study. Patients were further subgrouped according to their drug therapy. Serum neopterin concentrations were detected by ELISA. Urinary neopterin, biopterin, serum tryptophan (Trp) and kynurenine (Kyn) levels were detected by HPLC. There was no difference between controls and diabetes patients in serum neopterin, urinary neopterin and biopterin levels (p > 0.05, all). Serum Trp and Kyn levels were significantly different in type 1 diabetes (T1DM) patients compared to controls (p < 0.05, both). Serum neopterin levels were significantly higher in type 2 diabetes patients (T2DM) compared to T1DM (p < 0.05). Urinary biopterin levels of T2DM patients using both metformin and vildagliptin were significantly higher than T1DM patients (p < 0.05). The correlations between serum neopterin and urinary neopterin, Kyn and Kyn/Trp were statistically significant in control and patient groups (p < 0.05, all). The study showed that Kyn/Trp was altered in diabetes patients due to immune modulation. On the other hand, although xenobiotic exposure may change pteridine levels, metformin and/or vildagliptin use in T2DM patients did not have any effect on the measured parameters.
Identifiants
pubmed: 33046801
doi: 10.1038/s41598-020-74183-w
pii: 10.1038/s41598-020-74183-w
pmc: PMC7552423
doi:
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Biopterins
0
Kynurenine
343-65-7
Neopterin
670-65-5
Tryptophan
8DUH1N11BX
Metformin
9100L32L2N
Vildagliptin
I6B4B2U96P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17025Références
Federation, I. D. IDF Diabetes Atlas, https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/13-diabetes-atlas-seventh-edition.html (2015).
Bilous, E. D., E. Handbook of Diabetes. (Wiley-Blackwell, 2010).
Giacco, F. & Brownlee, M. Oxidative stress and diabetic complications. Circ. Res. 107, 1058–1070 (2010).
pubmed: 21030723
pmcid: 2996922
doi: 10.1161/CIRCRESAHA.110.223545
Einarson, T. R., Acs, A., Ludwig, C. & Panton, U. H. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc. Diabetol. 17, 83 (2018).
pubmed: 29884191
pmcid: 5994068
doi: 10.1186/s12933-018-0728-6
Viollet, B. et al. Cellular and molecular mechanisms of metformin: an overview. Clin. Sci. (Lond) 122, 253–270 (2012).
doi: 10.1042/CS20110386
Ahren, B., Pacini, G., Foley, J. E. & Schweizer, A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diab. Care 28, 1936–1940 (2005).
doi: 10.2337/diacare.28.8.1936
Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P. & Garg, R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111, 1448–1454 (2005).
pubmed: 15781756
doi: 10.1161/01.CIR.0000158483.13093.9D
pmcid: 15781756
Wolff, S. P., Jiang, Z. Y. & Hunt, J. V. Protein glycation and oxidative stres in diabetes mellitus and ageing. Free Radic. Biol. Med. 10, 339–352 (1991).
pubmed: 1855674
doi: 10.1016/0891-5849(91)90040-A
pmcid: 1855674
Kaneto, H. et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48, 2398–2406 (1999).
pubmed: 10580429
doi: 10.2337/diabetes.48.12.2398
pmcid: 10580429
de Oliveira, V. N. et al. The effect of different training programs on antioxidant status, oxidative stress, and metabolic control in type 2 diabetes. Appl. Physiol. Nutr. Metab. 37, 334–344 (2012).
pubmed: 22458821
doi: 10.1139/h2012-004
pmcid: 22458821
Aydin, A. et al. Oxidative stress and nitric oxide related parameters in type II diabetes mellitus: effects of glycemic control. Clin. Biochem. 34, 65–70 (2001).
pubmed: 11239518
doi: 10.1016/S0009-9120(00)00199-5
pmcid: 11239518
Pfleiderer, W. Pteridines. Properties, reactivities and biological significance. J Heterocyclic Chem29, 583–605 (1992).
Gieseg, S. P., Baxter-Parker, G. & Lindsay, A. Neopterin, inflammation, and oxidative stress: what could we be missing? Antioxidants (Basel)7, 80 (2018).
Bendall, J. K., Douglas, G., McNeill, E., Channon, K. M. & Crabtree, M. J. Tetrahydrobiopterin in cardiovascular health and disease. Antioxid. Redox Sign. 20, 3040–3077 (2014).
doi: 10.1089/ars.2013.5566
Thony, B., Auerbach, G. & Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347(Pt 1), 1–16 (2000).
pubmed: 10727395
pmcid: 1220924
doi: 10.1042/bj3470001
Plata-Nazar, K. J., A. Clinical usefulness of determining the concentration of neopterin. Pteridines22, 77–89 (2011).
Schrocksnadel, K., Wirleitner, B., Winkler, C. & Fuchs, D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 364, 82–90 (2006).
pubmed: 16139256
doi: 10.1016/j.cca.2005.06.013
pmcid: 16139256
King, N. J. & Thomas, S. R. Molecules in focus: indoleamine 2,3-dioxygenase. Int. J. Biochem. Cell Biol. 39, 2167–2172 (2007).
pubmed: 17320464
doi: 10.1016/j.biocel.2007.01.004
pmcid: 17320464
Chen, Y. & Guillemin, G. J. Kynurenine pathway metabolites in humans: disease and healthy States. IJTR 2, 1–19 (2009).
pubmed: 22084578
doi: 10.4137/IJTR.S2097
Yuksel, O. et al. Neopterin, catalase and superoxide dismutase in females with benign and malignant breast tumors. Pteridines 18, 132–138 (2007).
doi: 10.1515/pteridines.2007.18.1.132
Sahin, T. T., Yuksel, O., Girgin, G., Sipahi, H., Dikmen, K, Azili, C., Taneri, F. & Baydar, T. Is neopterin level a predictive and differential biomarker in patients with thyroid disorders? J Endocrinol Invest32, 147–149 (2009).
Widner, B., Werner, E. R., Schennach, H., Wachter, H. & Fuchs, D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem 43, 2424–2426 (1997).
pubmed: 9439467
doi: 10.1093/clinchem/43.12.2424
pmcid: 9439467
Girgin, G. et al. Tryptophan degradation and serum neopterin concentrations in intensive care unit patients. Toxicol. Mech. Meth. 21, 231–235 (2011).
doi: 10.3109/15376516.2010.545960
Dominguez-Rodriguez, A. et al. Usefulness of serum neopterin levels in acute decompensated heart failure to predict renal dysfunction. Biomarkers 17, 134–139 (2012).
pubmed: 22188331
doi: 10.3109/1354750X.2011.643486
pmcid: 22188331
Oxenkrug, G. F. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann. NY Acad. Sci. 1199, 1–14 (2010).
pubmed: 20633104
doi: 10.1111/j.1749-6632.2009.05356.x
pmcid: 20633104
Oxenkrug, G. F. Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders. J. Neural. Transm. (Vienna) 118, 75–85 (2011).
doi: 10.1007/s00702-010-0475-7
Murr, C., Widner, B., Wirleitner, B. & Fuchs, D. Neopterin as a marker for immune system activation. Curr. Drug Metab. 3, 175–187 (2002).
pubmed: 12003349
doi: 10.2174/1389200024605082
pmcid: 12003349
Widner, B., Wirleitner, B., Baier-Bitterlich, G., Weiss, G. & Fuchs, D. Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch. Immunol. Ther. Exp. 48, 251–258 (2000).
Grossmann, V. et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diab. Care 38, 1356–1364 (2015).
doi: 10.2337/dc14-3008
Unuvar, S., Tanriverdi, Z. & Aslanhan, H. Potential prognostic role of immune system activation marker neopterin in patients with type 2 diabetes. J. Med. Biochem. 37, 465–469 (2018).
pubmed: 30584406
pmcid: 6298474
doi: 10.2478/jomb-2018-0004
Al-Nimer, M. S. & Dezayee, Z. M. I. Assessment of serum neopterin as an inflammatory and cardiovascular marker in type 1 and 2 diabetes complicated by diabetic foot syndrome: a comparative study. Clin. Diabetol. 7, 91–96 (2018).
doi: 10.5603/DK.2018.0002
Elbarbarya, N. S., Ismail, E. A. R., El-Hilaly, R. A. & Ahmed, F. S. Role of neopterin as a biochemical marker for peripheral neuropathy in pediatric patients with type 1 diabetes: Relation to nerve conduction studies. Int. Immunophar. 59, 68–75 (2018).
doi: 10.1016/j.intimp.2018.03.026
Weiss, M. F., Rodby, R. A., Justice, A. C. & Hricik, D. E. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy Collaborative Study Group. Kidney Int. 54, 193–202 (1998).
pubmed: 9648079
doi: 10.1046/j.1523-1755.1998.00982.x
pmcid: 9648079
Palabiyik, ŞS. et al. Evaluation of dihydropteridine reductase activities in patients with kidney failure. Pteridines 24, 219–223 (2013).
doi: 10.1515/pterid-2013-0030
Berdowska, A. & Zwirska-Korczala, K. Neopterin measurement in clinical diagnosis. J. Clin. Pharm. Ther. 26, 319–329 (2001).
pubmed: 11679022
doi: 10.1046/j.1365-2710.2001.00358.x
pmcid: 11679022
Ipekci, S. H. et al. Serum levels of neopterin in gestational diabetes mellitus: the relationship with Apgar scores. Arch. Gynecol. Obst. 292, 103–109 (2015).
doi: 10.1007/s00404-015-3615-3
Karaca, A., Omma, T., Dura Deveci, C., Bakar, F. & Doğan, K. Neopterin and hsCRP are not correlated in gestational diabetes mellitus. Gynecol. Endocrinol.32, 977–981 (2016).
McLaughlin, T. et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscl. Throm. Vas. 34, 2637–2643 (2014).
doi: 10.1161/ATVBAHA.114.304636
Harford, K. A., Reynolds, C. M., McGillicuddy, F. C. & Roche, H. M. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. P. Nutr. Soc. 70, 408–417 (2011).
doi: 10.1017/S0029665111000565
Nekoua, M. P. et al. Modulation of immune cells and Th1/Th2 cytokines in insulin-treated type 2 diabetes mellitus. Afr. Health Sci. 16, 712–724 (2016).
pubmed: 27917204
pmcid: 5111983
doi: 10.4314/ahs.v16i3.11
Sireesh, D., Dhamodharan, U., Ezhilarasi, K., Vijay, V. & Ramkumar, K. M. Association of NF-E2 related factor 2 (Nrf2) and inflammatory cytokines in recent onset type 2 diabetes mellitus. Sci. Rep 8, 5126 (2018).
pubmed: 29572460
pmcid: 5865120
doi: 10.1038/s41598-018-22913-6
Ursini, F. et al. Metformin and autoimmunity: a “new deal” of an old drug. Front. Immunol. 9, 1236 (2018).
pubmed: 29915588
pmcid: 5994909
doi: 10.3389/fimmu.2018.01236
Marcucci, F., Romeo, E., Caserta, C. A., Rumio, C. & Lefoulon, F. Context-dependent pharmacological effects of metformin on the immune system. Trends Pharmacol. Sci. 41, 162–171 (2020).
pubmed: 32033771
doi: 10.1016/j.tips.2020.01.003
pmcid: 32033771
Shao, S. Y., Xu, Q. Q., Yu, X. F., Pan, R. P. & Chen, Y. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharmacol. Therapeut. 209, 107503 (2020).
doi: 10.1016/j.pharmthera.2020.107503
Kovacovicova, K. & Vinciguerra, M. Inhibition of dipeptidyl peptidase 4 (DPP4) activates immune cells chemotaxis in hepatocellular carcinoma. Oncol. Sig. 2, 1–3 (2019).
doi: 10.1016/j.onsig.2019.08.001
Pinheiro, M. M. et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. Eur. J. Pharm. Sci. 100, 17–24 (2017).
pubmed: 28065853
doi: 10.1016/j.ejps.2016.12.040
pmcid: 28065853
Lanser, L. et al. Inflammation-induced tryptophan breakdown is related with anemia, fatigue, and depression in cancer. Front. Immunol. 11, 249 (2020).
pubmed: 32153576
pmcid: 7047328
doi: 10.3389/fimmu.2020.00249
Weitgasser, R. et al. Antibodies to heat-shock protein 65 and neopterin levels in patients with type 1 diabetes mellitus. Exp. Clin. Endocrinol. Diab. 111, 127–131 (2003).
doi: 10.1055/s-2003-39784
Widner, B. et al. Tryptophan degradation and immune activation in Alzheimer’s disease. J. Neural. Transm. 107, 343–353 (2000).
pubmed: 10821443
doi: 10.1007/s007020050029
pmcid: 10821443
Ozkan, Y., Mete, G., Sepici-Dincel, A., Sepici, V. & Simsek, B. Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients. Clin. Rheumatol. 31, 29–34 (2012).
pubmed: 21556779
doi: 10.1007/s10067-011-1767-5
pmcid: 21556779
Schroecksnadel, K. et al. Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin. Rheumatol. 25, 334–337 (2006).
pubmed: 16261283
doi: 10.1007/s10067-005-0056-6
pmcid: 16261283
Palabiyik, S. S. et al. Neopterin release and tryptophan degradation in patients with uveitis. Curr. Eye Res. 41, 1513–1517 (2016).
pubmed: 27159029
doi: 10.3109/02713683.2015.1133830
pmcid: 27159029